In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsMucosal damage and neutropenia are required for Candida albicans disseminationVoriconazole pharmacokinetics and pharmacodynamics in children.Voriconazole pharmacokinetics in liver transplant recipients.Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosisCorrelation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studiesDerivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectObservational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis.Achieving target voriconazole concentrations more accurately in children and adolescents.Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Antifungal pharmacokinetics and pharmacodynamicsResponse of a clinical Escherichia coli strain to repeated cefquinome exposure in a piglet tissue-cage model.Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisTherapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Coordinated roles of pregnane X receptor and constitutive androstane receptor in autoinduction of voriconazole metabolism in mice.Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serumAssociation of fluconazole pharmacodynamics with mortality in patients with candidemiaPractice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Animal models: an important tool in mycology.Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin
P2860
Q27009221-90B3142D-0D24-46F0-9095-EAF0C42B7ACFQ27025299-9298E36D-283E-4222-8536-A8D12B20F6B8Q33320189-DE47BD10-208C-4AB0-8352-6DA74AF5D69EQ33577291-5D0F36AE-91CD-46DB-AE32-D43D59058068Q33613685-1D268839-5DAC-4C76-89EF-BA5752F17C63Q33859215-52BC9242-484E-4C69-A3DF-332EE0C6F2D0Q33876423-39C08971-7B6A-46DD-9F74-8595766ED6B0Q33938082-9306EF25-90AB-4169-B17E-68043B965DD2Q34077069-AE3F58B4-2C91-46E0-BC3D-CA57C2C396A1Q34141420-7E634DF6-D6F3-4928-AA36-CFDF5FA66D1FQ34142328-230125FE-1D6F-49FF-8B8C-4D04557A0FEBQ34150943-2561E099-8821-430A-AFF7-6B6779B96BF8Q34290034-BC95EAE5-0370-41FE-86B2-73932AB6B92DQ34431984-0A1F0B53-598B-4194-95A2-276AD3FC753EQ35004898-7FAF31EB-DF14-400D-AC36-97318CC03610Q35113648-FC5854D0-6A2B-4FBB-B60C-43023B7C3949Q35127913-DB55863C-B18E-4AAB-AEA7-C3BCB7326910Q35270270-CE115F33-11C3-44BE-95AF-A3E4C5DE5C91Q35270948-0E202973-F538-4300-A447-58CCBA9B985DQ35607652-E9C727B7-319F-46C2-9A34-C54462DA42FAQ35635693-0535C51F-D4BB-429A-91C5-F55F5735F4E3Q35635830-890693B7-65CF-482F-9DD2-A4BD74F2FF65Q35663841-B62CB1A9-7EBA-4BF7-A445-686F2712DD05Q35712872-F4592F1D-D87F-4B9A-BF95-3132A3E83B2DQ35714132-572C4EC4-F3C5-49FB-92F4-2A7830CD58EEQ35912756-C71C49E7-5D68-4692-9036-9564795310D7Q35973357-6288D795-5636-4251-BDBB-2C7A847906FDQ36018595-B123F9AE-E7CF-417C-BA96-C76CE04455DAQ36172497-90F9B4B7-E881-4C59-8A60-723709BB1860Q36364100-7800EFC9-C875-44C8-B20E-CCEDD2AD9DFAQ36482785-8301A79D-5C41-449A-84F2-872B92247561Q36505539-7E974F43-F295-4275-AF04-9E00E28362B2Q36608562-F81B0706-D383-47B4-A4F8-9BAE5F2B6B0BQ36667044-5D2FACA3-6CDA-46C5-9D16-91443A640F1CQ36744831-5C01CA88-5083-47DD-820C-03D201C4DA04Q36757617-8D7C94B1-57E6-4426-90E3-4E7D47880D54Q36870712-C17D57FC-899E-4A65-910A-ABF6EDF06DD2Q36927577-19F60F38-6E45-4DCD-AF82-FFA3BDFCC9BFQ37008692-CA6867B6-3B41-430B-9564-2E808DA56D07Q37190801-4575FFA1-430E-4C24-848D-8206863E60BE
P2860
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
In vivo pharmacokinetics and p ...... in a murine candidiasis model.
@ast
In vivo pharmacokinetics and p ...... in a murine candidiasis model.
@en
type
label
In vivo pharmacokinetics and p ...... in a murine candidiasis model.
@ast
In vivo pharmacokinetics and p ...... in a murine candidiasis model.
@en
prefLabel
In vivo pharmacokinetics and p ...... in a murine candidiasis model.
@ast
In vivo pharmacokinetics and p ...... in a murine candidiasis model.
@en
P2093
P2860
P1476
In vivo pharmacokinetics and p ...... in a murine candidiasis model
@en
P2093
K Marchillo
T Stamstad
P2860
P304
P356
10.1128/AAC.47.10.3165-3169.2003
P407
P50
P577
2003-10-01T00:00:00Z